Oral anticoagulants in development: focus on thromboprophylaxis in patients undergoing orthopaedic surgery (Q36564967)

15 August 2017

1 reference

title

Oral anticoagulants in development: focus on thromboprophylaxis in patients undergoing orthopaedic surgery (English)

1 reference

15 August 2017

1 reference

1 reference

2

Daniel J Quinlan

1 reference

15 August 2017

Bengt I Eriksson

1

1 reference

15 August 2017

1 January 2006

1 reference

15 August 2017

1 reference

15 August 2017

66

1 reference

15 August 2017

11

1 reference

15 August 2017

1411-1429

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-200666110-00001

15 August 2017

0 references

cites work

Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00003495-200666110-00001

Extended out-of-hospital low-molecular-weight heparin prophylaxis against deep venous thrombosis in patients after elective hip arthroplasty: a systematic review

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00003495-200666110-00001

Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor

21 January 2018

1 reference

12 December 2020

The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy

1 reference

12 December 2020

Superiority of fondaparinux over enoxaparin in preventing venous thromboembolism in major orthopedic surgery using different efficacy end points

1 reference

12 December 2020

Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery

1 reference

12 December 2020

Subcutaneous Fondaparinux versus Intravenous Unfractionated Heparin in the Initial Treatment of Pulmonary Embolism

1 reference

12 December 2020

Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement.

1 reference

12 December 2020

BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study

1 reference

12 December 2020

Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement

1 reference

12 December 2020

BIBR-1048 Boehringer Ingelheim

1 reference

12 December 2020

A review of the oral direct thrombin inhibitor ximelagatran: not yet the end of the warfarin era...

1 reference

12 December 2020

Incidence and time course of thromboembolic outcomes following total hip or knee arthroplasty

1 reference

12 December 2020

Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939--an oral, direct Factor Xa inhibitor--after multiple dosing in healthy male subjects

1 reference

12 December 2020

New oral anticoagulants show promise

1 reference

12 December 2020

Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement: a phase 2 dose-finding study

1 reference

12 December 2020

A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial.

1 reference

12 December 2020

New pentasaccharides for the prophylaxis of venous thromboembolism: clinical studies

1 reference

12 December 2020

Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies.

1 reference

12 December 2020

Discovery of the novel antithrombotic agent 5-chloro-N-({(5S)-2-oxo-3- [4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene- 2-carboxamide (BAY 59-7939): an oral, direct factor Xa inhibitor

1 reference

12 December 2020

Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement.

1 reference

12 December 2020

New heparin complexes active by intestinal absorption: I-multiple ion pairs with basic organic compounds

1 reference

12 December 2020

The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study

1 reference

12 December 2020

Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy

1 reference

12 December 2020

Determination of endogenous glycosaminoglycans derived disaccharides in human plasma by HPLC: validation and application in a clinical study

1 reference

12 December 2020

Direct thrombin inhibitors

1 reference

12 December 2020

New anticoagulants: beyond heparin, low-molecular-weight heparin and warfarin

1 reference

12 December 2020

Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients

1 reference

12 December 2020

Percentage of inadequate phlebograms and observer agreement in thromboprophylactic multicenter trials using standardized methodology and central assessment

1 reference

12 December 2020

Structure-based design of novel potent nonpeptide thrombin inhibitors

1 reference

12 December 2020

Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement

1 reference

12 December 2020

Efficacy and safety of fondaparinux in major orthopedic surgery according to the timing of its first administration.

1 reference

12 December 2020

Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects.

1 reference

12 December 2020

Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery: a multicenter, randomized, placebo-controlled, double-blind study

1 reference

12 December 2020

Extended-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of the randomised trials

1 reference

12 December 2020

Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO I.

1 reference

12 December 2020

Central assessment of bilateral phlebograms in a major multicentre thromboprophylactic trial. Reasons for inadequate results.

1 reference

12 December 2020

Small molecule coagulation cascade inhibitors in the clinic

1 reference

12 December 2020

Preoperative or postoperative start of prophylaxis for venous thromboembolism with low-molecular-weight heparin in elective hip surgery?

1 reference

12 December 2020

Low-molecular-weight heparin prophylaxis using dalteparin in close proximity to surgery vs warfarin in hip arthroplasty patients: a double-blind, randomized comparison. The North American Fragmin Trial Investigators

1 reference

12 December 2020

1 reference

12 December 2020

Prevention of venous thromboembolism following orthopaedic surgery: clinical potential of direct thrombin inhibitors

1 reference

12 December 2020

10.2165/00003495-200666110-00001

Identifiers

DOI

1 reference

PubMed ID

16906775

Dimensions Publication ID

15 August 2017

0 references

1 reference

PubMed ID

16906775